Five-year Biomarker Progression Variability for Alzheimer's Disease Dementia Prediction: Can a Complex Instrumental Activities of Daily Living Marker Fill in the Gaps?

Overview

Journal Alzheimers Dement (Amst)

Date 2016 May 31

PMID 27239530

Citations 18

Authors

Ioannis Tarnanas

Anthoula Tsolaki

Mark Wiederhold

Brenda Wiederhold

Magda Tsolaki

Affiliations

Soon will be listed here.

Abstract

Introduction: Biomarker progressions explain higher variability in cognitive decline than baseline values alone. This study examines progressions of established biomarkers along with a novel marker in a longitudinal cognitive decline.

Methods: A total of 215 subjects were used with a diagnosis of normal, mild cognitive impairment (MCI) or Alzheimer's disease (AD) at baseline. We calculated standardized biomarker progression rates and used them as predictors of outcome within 5 years.

Results: Early cognitive declines were more strongly explained by fluorodeoxyglucose-positron emission tomography, precuneus and medial temporal cortical thickness, and the complex instrumental activities of daily living (iADL) marker progressions. Using Cox proportional hazards model, we found that these progressions were a significant risk factor for conversion from both MCI to AD (adjusted hazard ratio 1.45; 95% confidence interval 1.20-1.93; P = 1.23 × 10(-5)) and cognitively normal to MCI (adjusted hazard ratio 1.76; 95% confidence interval 1.32-2.34; P = 1.55 × 10(-5)).

Discussion: Compared with standard biological biomarkers, complex functional iADL markers could also provide predictive information for cognitive decline during the presymptomatic stage. This has important implications for clinical trials focusing on prevention in asymptomatic individuals.

Citing Articles

RADAR-AD: assessment of multiple remote monitoring technologies for early detection of Alzheimer's disease.

Lentzen M, Vairavan S, Muurling M, Alepopoulos V, Atreya A, Boada M Alzheimers Res Ther. 2025; 17(1):29.

PMID: 39865315 PMC: 11771057. DOI: 10.1186/s13195-025-01675-0.

Digital Health Technologies for Alzheimer's Disease and Related Dementias: Initial Results from a Landscape Analysis and Community Collaborative Effort.

Lott S, Streel E, Bachman S, Bode K, Dyer J, Fitzer-Attas C J Prev Alzheimers Dis. 2024; 11(5):1480-1489.

PMID: 39350395 PMC: 11436391. DOI: 10.14283/jpad.2024.103.

Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review.

Garcia M, Leadley R, Ross J, Bozeat S, Redhead G, Hansson O J Alzheimers Dis Rep. 2024; 8(1):203-240.

PMID: 38405341 PMC: 10894607. DOI: 10.3233/ADR-230045.

Augmented reality versus standard tests to assess cognition and function in early Alzheimer's disease.

Muurling M, de Boer C, Vairavan S, Harms R, Chadha A, Tarnanas I NPJ Digit Med. 2023; 6(1):234.

PMID: 38110486 PMC: 10728213. DOI: 10.1038/s41746-023-00978-6.

Eliciting brain waves of people with cognitive impairment during meditation exercises using portable electroencephalography in a smart-home environment: a pilot study.

Lazarou I, Oikonomou V, Mpaltadoros L, Grammatikopoulou M, Alepopoulos V, Stavropoulos T Front Aging Neurosci. 2023; 15:1167410.

PMID: 37388185 PMC: 10306118. DOI: 10.3389/fnagi.2023.1167410.

References

Leoutsakos J, Bartlett A, Forrester S, Lyketsos C . Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example. Alzheimers Dement. 2013; 10(2):152-61. PMC: 3925200. DOI: 10.1016/j.jalz.2013.05.1776. View

Noel-Storr A, Flicker L, Ritchie C, Nguyen G, Gupta T, Wood P . Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimers Dement. 2012; 9(3):e96-e105. DOI: 10.1016/j.jalz.2012.01.014. View

Caroli A, Prestia A, Chen K, Ayutyanont N, Landau S, Madison C . Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med. 2012; 53(4):592-600. PMC: 3640308. DOI: 10.2967/jnumed.111.094946. View

Toyn J . What lessons can be learned from failed Alzheimer's disease trials?. Expert Rev Clin Pharmacol. 2015; 8(3):267-9. DOI: 10.1586/17512433.2015.1034690. View

Kvartsberg H, Duits F, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K . Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 2014; 11(10):1180-90. DOI: 10.1016/j.jalz.2014.10.009. View

Dickerson B, Wolk D . Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau. Front Aging Neurosci. 2013; 5:55. PMC: 3795312. DOI: 10.3389/fnagi.2013.00055. View

Gibbons L, Carle A, Mackin R, Harvey D, Mukherjee S, Insel P . A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012; 6(4):517-27. PMC: 3684181. DOI: 10.1007/s11682-012-9176-1. View

Edmonds E, Delano-Wood L, Clark L, Jak A, Nation D, McDonald C . Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement. 2014; 11(4):415-24. PMC: 4241187. DOI: 10.1016/j.jalz.2014.03.005. View

Ye B, Seo S, Yang J, Kim H, Kim Y, Yoon C . Comparison of cortical thickness in patients with early-stage versus late-stage amnestic mild cognitive impairment. Eur J Neurol. 2013; 21(1):86-92. DOI: 10.1111/ene.12251. View

10.

Prestia A, Caroli A, Herholz K, Reiman E, Chen K, Jagust W . Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimers Dement. 2013; 9(6):677-86. PMC: 4058442. DOI: 10.1016/j.jalz.2012.09.016. View

11.

Brickman A, Schupf N, Manly J, Stern Y, Luchsinger J, Provenzano F . APOE ε4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role?. Alzheimers Dement. 2014; 10(6):619-29. PMC: 4252241. DOI: 10.1016/j.jalz.2014.07.155. View

12.

Tom Kodamullil A, Younesi E, Naz M, Bagewadi S, Hofmann-Apitius M . Computable cause-and-effect models of healthy and Alzheimer's disease states and their mechanistic differential analysis. Alzheimers Dement. 2015; 11(11):1329-39. DOI: 10.1016/j.jalz.2015.02.006. View

13.

Lim Y, Maruff P, Pietrzak R, Ellis K, Darby D, Ames D . Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimers Dement. 2014; 10(6):743-751.e1. DOI: 10.1016/j.jalz.2013.11.005. View

14.

Della Rosa P, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I . A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014; 12(4):575-93. DOI: 10.1007/s12021-014-9235-4. View

15.

Tarnanas I, Schlee W, Tsolaki M, Muri R, Mosimann U, Nef T . Ecological validity of virtual reality daily living activities screening for early dementia: longitudinal study. JMIR Serious Games. 2015; 1(1):e1. PMC: 4307822. DOI: 10.2196/games.2778. View

16.

Silbert L, Dodge H, Perkins L, Sherbakov L, Lahna D, Erten-Lyons D . Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology. 2012; 79(8):741-7. PMC: 3421153. DOI: 10.1212/WNL.0b013e3182661f2b. View

17.

Geuze E, Vermetten E, Bremner J . MR-based in vivo hippocampal volumetrics: 1. Review of methodologies currently employed. Mol Psychiatry. 2004; 10(2):147-59. DOI: 10.1038/sj.mp.4001580. View

18.

Grill J, Di L, Lu P, Lee C, Ringman J, Apostolova L . Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging. 2012; 34(1):62-72. PMC: 3412892. DOI: 10.1016/j.neurobiolaging.2012.03.006. View

19.

Drachman D . The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement. 2014; 10(3):372-80. DOI: 10.1016/j.jalz.2013.11.003. View

20.

Herrup K, Carrillo M, Schenk D, Cacace A, DeSanti S, Fremeau R . Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement. 2013; 9(4):452-458.e1. PMC: 3983562. DOI: 10.1016/j.jalz.2013.01.017. View